Domainex is a leading integrated drug discovery CRO and has been setting the highest standards in drug discovery, with a particular emphasis on small molecule research, since 2001. We work in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world.
Proven Track Record of Success
We offer you tailored services for every step of the drug discovery process, from expression of recombinant proteins and screening against disease targets to identify hit compounds, through the design and medicinal chemistry optimisation of hits and leads, to take these all the way to your pre-clinical drug candidates. Our multidisciplinary team of scientists works closely with you to generate innovative ideas, and to deliver high-quality results and outputs (e.g. crystallography-grade proteins and novel compounds that meet the desired target product profile), whilst at all times upholding the very highest standards of confidentiality. We have established a strong reputation with a very high level of repeat business and a proven record of success, some of which we can illustrate through the publications and case studies our clients have allowed us to put in the public domain.
Innovative and Customised Services
We integrate seamlessly our innovative and customised biology and chemistry services to advance your disease research projects in a timely and efficient way. Our experience spans a broad range of therapeutic areas, including oncology, inflammation, respiratory and cardiovascular diseases. We have expertise across a wide range of drug target classes, including protein-protein interactions, epigenetic targets (e.g. lysine methyltransferases), a wide range of enzymes (including kinases and proteases),ion channels, and G-protein coupled receptors (GPCRs). Whatever the research phase of your project, we have an unrivalled track record of solving complex challenges.
Highly Qualified and Experienced Scientists
Ultimately what determines the success of your project are our scientists – who become committed members of your team, and an extension of your own resources. Our multi-disciplinary team of ~ 70 scientists has a wealth of experience in drug discovery – on average over 12 years per scientist. About 80% of our scientists are PhD qualified and most have previous experience gained from a variety of pharmaceutical and biotechnology companies as well as from leading academic institutes.
We invite you to find out more about our capabilities, to get to know us and to talk to us about your drug discovery requirements. We will provide you with comprehensive proposals for your consideration within a short time frame. We appreciate that the primary objective will be to enrich your medicines pipeline in a timely, cost-effective and value-creating manner.
We look forward to hearing from you.